Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2

SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Wanbo, Zhang, Xiujuan, He, Yuxian, Jiang, Shibo, Du, Lanying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219369/
https://www.ncbi.nlm.nih.gov/pubmed/32405117
http://dx.doi.org/10.1016/j.antiviral.2020.104820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219369/
https://www.ncbi.nlm.nih.gov/pubmed/32405117
http://dx.doi.org/10.1016/j.antiviral.2020.104820

Ejemplares similares